Home > Animal Health & Nutrition > Veterinary Pharmaceuticals > Pet Monoclonal Antibodies Market

Pet Monoclonal Antibodies Market Trends

Report ID: GMI10496
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Pet Monoclonal Antibodies Market Trends

Advancements in monoclonal antibodies propel market growth by facilitating precise therapies that effectively combat diseases such as cancer, infectious diseases, and immune disorders. Continuous research and technological advancements support veterinary professionals in utilizing these targeted treatments, thereby increasing demand throughout the global animal healthcare sector.

For instance, in July 2023, Invetx's development of species-specific, half-life extension technology for dogs and cats represented a significant advancement in pet monoclonal antibodies. This innovation confirmed the superior efficacy and prolonged activity of their therapies, enhancing treatment outcomes for chronic and serious diseases in pets. This patented technology underscored advancement in optimizing antibody drug treatments, potentially setting new standards in veterinary care.
As a result, veterinarians and pet owners may increasingly favour these advanced therapies for their efficacy and extended duration, thereby driving demand in the pet monoclonal antibodies market globally.

Furthermore, the growing animal healthcare expenditure, growing government support, and strategic expansions by major players further propel the market demand.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The pet monoclonal antibodies market size was valued at USD 967.3 million in 2023 and is estimated to grow at 14.2% CAGR from 2024 to 2032, owing to the rising incidence of chronic diseases.

The dog segment in the market recorded USD 715.9 million in 2023 and will grow at 14.1% CAGR during 2024-2032, driven by the high prevalence of chronic and infectious diseases among dogs.

U.S. pet monoclonal antibodies market size accounted for USD 432.9 million in 2023 and is anticipated to grow rapidly through 2032, owing to high pet ownership rates, and significant investment in R&D.

Ceva Santé Animale, Boehringer Ingelheim International GmbH, Elanco Animal Health, Merck Animal Health, Sanofi, Vetigenics, and Zoetis Inc. among others.